Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Source: Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases (2015) Claim 3: Suppression of MYC target genes and oxidative phosphorylation are features of longevity-associated interventions
Gentle on the stomach, suitable for individuals with sensitivities
Tolerability (human reports): Small uncontrolled reports describe NAD+ infusions as generally tolerated, with dose-related flushing and GI effects
Brubaker says drugs need to be carefully tested in stages before they are approved for use in people
dates 1/1/23 3/9/26
Not evaluated by the TGA or any regulatory authority for safety or efficacy in humans or animals
